Urology Case Reports (Nov 2016)
Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
- Hyun Kim,
- Mohammed Alshalalfa,
- Jean Hoffman-Censits,
- Costas D. Lallas,
- Elai Davicioni,
- Jianqing Lin,
- Ruth Birbe,
- Nicholas Erho,
- Jonathan Lehrer,
- Hussam Al-Deen Ashab,
- Mandeep Takhar,
- Anders Olson,
- Lucia L.C. Lam,
- W. Kevin Kelly,
- Karen E. Knudsen,
- Chellappagounder Thangavel,
- Roland Seiler,
- Felix Y. Feng,
- Edward M. Schaeffer,
- Edouard J. Trabulsi,
- Leonard G. Gomella,
- Mark D. Hurwitz,
- Adam P. Dicker,
- Robert B. Den
Affiliations
- Hyun Kim
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Mohammed Alshalalfa
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- Jean Hoffman-Censits
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Costas D. Lallas
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Elai Davicioni
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- Jianqing Lin
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Ruth Birbe
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Nicholas Erho
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- Jonathan Lehrer
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- Hussam Al-Deen Ashab
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- Mandeep Takhar
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- Anders Olson
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- Lucia L.C. Lam
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- W. Kevin Kelly
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Karen E. Knudsen
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Chellappagounder Thangavel
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Roland Seiler
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
- Felix Y. Feng
- Department of Radiation Oncology, University of California, San Francisco, CA, USA
- Edward M. Schaeffer
- Department of Urology, Feinberg School of Medicine, Northwestern University, IL, USA
- Edouard J. Trabulsi
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Leonard G. Gomella
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Mark D. Hurwitz
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Adam P. Dicker
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- Robert B. Den
- Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA
- DOI
- https://doi.org/10.1016/j.eucr.2016.08.010
- Journal volume & issue
-
Vol. 9,
no. C
pp. 51 – 54
Abstract
Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.
Keywords
